 The FDA has signed off I-Mab NASDAQ: IMAB Investigational New Drug IND application for Protollin, an Alzheimers candidate. Brigham and Womens Hospital and Inspirevax granted I-Mab and Nhwa global exclusive licenses to develop, manufacture, and commercialize Protollin. 